Background: In dogs, as in humans, C-reactive protein (CRP) is a major acute phase protein that is rapidly and prominently increased after exposure to inflammatory stimuli. CRP measurements are used in the diagnosis and monitoring of infectious and inflammatory diseases.
INTRODUCTION
several hundred times that of preinflammation concentrations. 2 Consequently, CRP has been established as a powerful biomarker for the detection and monitoring of inflammation and infection in human and veterinary medicine. 1 Canine CRP (cCRP) concentration increases in a variety of common infectious and inflammatory diseases. [1] [2] [3] Specifically, it has been reported to be a diagnostic test in dogs with steroid-responsive meningitis-arteritis (SRMA) 1, 4 , for early detection of postsurgical complications 5 , and for monitoring disease progression and treatment efficiency in diseases such as pyometra 5, 6 , bacterial pneumonia 7 , and the systemic inflammatory response syndrome (SIRS). 8 Interestingly, cCRP measurements can also be used to screen for occult disease in clinically healthy appearing dogs. 1, 9 Although CRP is a valuable biomarker, its inclusion in routine biochemical profiles of dogs has been limited for years, mainly due to the lack of adequate commercial analytic methods appropriate for clinical laboratories. To our knowledge, the first commercially available cCRP assay, at least in Europe, was an ELISA. 10 However, ELISAs are not optimal for routine analysis in clinical laboratories because they have relatively high variability, are time-consuming, and are unsuitable for single-sample processing. An in-house turbidimetric immunoassay for cCRP had been previously developed 11 , but the assay was not available commercially. Automated turbidimetric immunoassays developed for human medicine with documented cross-reactivity with cCRP allowed the introduction of the CRP assay in routine biochemical panels in some veterinary laboratories, but these assays had serious limitations. 12, 13 For instance, the use of human calibrators prohibited the direct extrapolation of cCRP concentrations, but rather required reporting results interms of human CRP equivalents. This hurdle can be overcome by the use of a purified cCRP as calibrator. 14 However, the necessity to use human CRP specific antibodies for detection requires validation of every new batch because reactivity with the homologous dog protein can vary from lot to lot affecting assay accuracy. A nephelometric immunoassay for cCRP has been available in Japan for a while. 3 More recently several other canine-specific automated immunoassays have become commercially available, including turbidimetric immunoassays, as well as different point-of-care (POC) systems.
15-17
Here, we present a new automated particle-enhanced turbidimetric immunoassay for the measurement of cCRP based on antibodies against cCRP, and in combination with a canine CRP standard. The assay is now commercially available (Turbovet canine CRP, Acuvet Biotech, Zaragoza, Spain). As part of the validation study, the assay was compared with 2 other canine-specific commercial automated immunoassays: the Gentian method 15 and the Life Assays POC test (POCT). 16 
MATE RIALS AN D METHODS

Serum samples
cCRP turbidimetric immunoassay
The cCRP concentration was determined using immunoturbidimetry, which measured increased absorbance at 600 nm after dilution of the serum sample with a reaction buffer including latex immunoparticles. Previously, anti-cCRP antibodies were isolated from anti cCRP-specific rabbit antiserum 18 , followed by covalent fixation to carboxyl-modified polystyrene microparticles using the
ride] procedure, as previously described. 19 Assay calibration was performed with a multipoint calibration curve using a cCRP calibrator consisting of purified cCRP (150 mg/L) in a matrix based on a 0.1 M Tris Chloride, 0.15M NaCl, 3 mM CaCl 2 buffer at pH 7.4
and containing 10 mg/mL bovine serum albumin (BSA) and 0.09% sodium azide as a stabilizer. The development and establishment of the cCRP value in the calibration material by single radial immunodiffusion (SRID) using a cCRP standard serum has been previously described. 18 Serial dilutions of the calibrator were prepared by manually diluting the cCRP calibrator in 0.05M Tris Chloride, 0.15M NaCl, Final assay conditions used in the validation study are described in Table 1 . 20 Serum pools were analyzed in duplicate twice daily, with a minimum of 2 h between-runs. cCRP controls were included in each analytic run. The assay was calibrated once a week.
Results from 80 runs per sample were analyzed by 2-way nested ANOVA. Within-run, between-run, between-day, and within-laboratory precision (total precision) 20 were obtained and expressed as CV.
Linearity was evaluated by diluting a canine serum sample with a high cCRP concentration (140 mg/L) (designated S1) with a saline 
where l B is the mean concentration of the blank sample, r B is the SD of the blank cCRP sample concentrations, and r S is the SD of the low cCRP sample concentrations. 22 The limit of quantitation (LoQ) was evaluated according to CLSI guidelines in EP17-A2. 22 A canine serum sample containing 11 mg/L of cCRP was serially diluted, and each dilution was analyzed 8 times in 5 analytic runs (a total of 40 replicates). The total error (T e ) was calculated for each of the dilutions using the following equation:
T e = bias + 2SD. Bias was the difference between the analytic value obtained for the sample (mean value) and the expected value (calculated from the value determined in the undiluted sample multiplied by the dilution factor), expressed as an absolute value if the difference was negative. The T e was set at 29.6%. 15 Interference from hemoglobin, bilirubin, and triglycerides was evaluated by spiking canine serum with increasing amounts of the interferents, as previously described. 23 Solutions containing 98 g/L of hemoglobin prepared from a hemolysate, 6 g/L of bilirubin in (Table 5 ).
The interfering substance concentrations in the spiked samples were calculated taking into account the concentration of the concentrated solutions, the dilution factor used to prepare the samples, and the concentration of interferents in the control serum, which was set at zero. Samples were analyzed in duplicate and random order during a single run. Bias caused by the interferents (ie, differences between concentrations of cCRP in the sample containing the interfering substance and those of the control sample) were calculated and expressed as a percentage of the control serum. The presence of interference was defined as a bias ≥10%.
Method comparison
Method comparison was performed according to the ASVCP guidelines. 21 The new turbidimetric immunoassay was compared with 2 commercial assays: the Gentian cCRP assay (Gentian, Moss, Norway), which is a particle-enhanced turbidimetric immunoassay 15 , and the Life Assays cCRP assay (Life Assays, Lund, Sweden), which is a magnetic permeability-based POCT immunoassay, with the reagent based on anti-cCRP magnetic nanoparticles and silica microparticles, both carrying covalently linked antibodies directed at cCRP. 16 Measurement procedures were compared by linear regression analysis according to the nonparametric Passing and Bablok method 24 and by analysis of differences according to the Bland and Altman method. 25 A collection of 40 canine serum samples were analyzed with the 2 turbidimetric immunoassays using the same analyzer (Olympus AU400, Hamburg, Germany). All samples were measured in the same analytic run. Samples with cCRP values outside of the measurement range of the assays were excluded from the methods comparison study.
Samples were assayed randomly with the Life Assay method during 2 consecutive days because the Life Assays assay took 11 min per sample to determine cCRP concentrations.
RESULTS cCRP turbidimetric immunoassay
Specific anti-cCRP antibodies raised in rabbits were covalently fixed to latex microparticles to develop a turbidimetric immunoassay with enough sensitivity to determine cCRP concentrations in canine serum samples. Figure 1 shows the dose-response curve obtained with purified cCRP under optimized analytic conditions (Table 1) .
These conditions allowed a proportional cCRP measurement up to an achieved concentration of 150 mg/L, where a plateau was reached ( Figure 1 ). The analytic range up to 150 mg/L was used in the subsequent validation studies.
Validation study
Results of the imprecision study are shown in Table 2 . Within-run CV was <2% for all the samples, and total imprecision ranged from 1.52% (high cCRP samples) to 4.37% (low cCRP samples).
Linearity studies revealed that the assay measured proportionally in the analytic range up to 150 mg/L. A prozone effect was observed at concentrations >320 mg/L ( Figure 2 and Table 3 ).
Results of the limit of quantification (LoQ) study are shown in Table 4 . The assay LoD was 0.9 mg/L. The assay LoQ was established at 1.4 mg/L with a T e of 21%, which is lower than the total maximum allowable error of 29.6% previously determined based on the biological variation of cCRP. 26 The interference of hemoglobin, bilirubin, and triglycerides on cCRP measurements was evaluated (Table 5) . No interference was detected for any of these substances at any of the doses evaluated
The This benefit is further validated by the good agreement of results F I G U R E 1 . Dose-response curve of the turbidimetric immunoassay. Absorbance increases at 600 nm as a function of CRP concentration obtained with purified canine CRP with the assay conditions outlined in Table 1 .
T A B L E 2 . Results of the imprecision study on a new immunoturbidimetric canine CRP (cCRP) assay using an Olympus AU400 chemistry analyzer. Three samples with low (sample 1), medium (sample 2), and high (sample 3) cCRP concentrations were analyzed daily in duplicate in 2 analytical runs for 20 days. Withinrun, between-run, between-day, and within-laboratory (total) precision were obtained and expressed as CV as a percentage.
Between-run CV (%) The use of specific reagents is fundamental for the development of robust and accurate species-specific turbidimetric immunoassays.
Our antibodies are very specific because the antiserum is immunoadsorbed with canine serum deprived of cCRP. 18 Accordingly, the dose-response curve obtained with canine serum was similar to that obtained with purified cCRP, and no matrix effect was revealed in the linearity under dilution study.
The imprecision of the new cCRP turbidimetric immunoassay was very low: within-run CV was lower than 2% for all the samples tested, and total imprecision ranged from 1.52 (high cCRP sample) to 4.37% (low cCRP sample). These values are well within the maximum allowable imprecision of 12% previously suggested for cCRP determination, due to the biologic variability determined in healthy dogs. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The imprecision of our assay is similar to that reported for the Gentian cCRP assay 15 , and lower than that reported for the Randox method (intra-assay CV of 1-10% and inter-assay CV of 6-18%) 12 , the Life Assay (10% CV for samples with cCRP concentrations above 50 mg/ mL) 17 , and other POC systems such as the Teco Medical system (CV 19% for samples with CPR <20 mg/L), or the Eurolyser system (CV 14% for samples with cCRP concentrations of 50-100 mg/L). 17 Higher intra-and inter-assay CVs have also been reported for an ELISA method (in the range of 6.9-10.1% and 7.5-29.0%, respectively). T A B L E 3 . The prozone effect was evaluated by analyzing 2 serum samples (S2 and S3) containing 320 mg/mL and 460 mg/mL of canine CRP (cCRP), respectively, as determined by SRID. Additionally, the S3 serum sample was spiked with a solution of purified cCRP (3,100 mg/L) to yield a cCRP concentration of 600 mg/L (S4). Sample dilutions were carried out to yield a cCRP concentration falling into the measurement range of the assay, and the undiluted (S2-S4) and diluted samples were measured by the turbidimetric immunoassay. The measured value outlined in the table is the value obtained by the assay multiplied by the dilution factor. T A B L E 4 . To determine the limit of quantification (LoQ) of the turbidimetric immunoassay, a canine serum sample with a low canine CRP (cCRP) concentration was diluted to obtain samples with the expected values outlined in the first column (cCRP expected value). The samples were measured 40 times in 5 runs, and the mean, the SD, the bias with respect to the expected value, and the total error (T e ) were calculated. The LoQ of the assay was found to be 1.4 mg/ L with a T e of 21%. The security range could be increased (ie, the prozone effect would appear at a higher cCRP concentration) if the sample volume is reduced (eg, 2 lL instead of 3 lL). Our validation was performed with 3 lL of the samples because it is a volume adequate for all analyzers and allows an accurate measurement of the samples with low cCRP concentrations.
In the analytic conditions selected, the LoQ of the assay was 1.4 mg/L. This value is lower than those reported for other automated immunoassays such as the Gentian cCRP assay (7 mg/L) 15 , the Life Assay (7 mg/L), and other POC systems evaluated in the literature (10-20 mg/L). 17 Although these comparisons have to be taken with caution, due to the lack of harmonization among the different commercially available assays, the method described here immunoassay (up to 90% with 80 mg/dL hemoglobin). 2, 11 This artifact is eliminated with our particle-enhanced method because it measures at 600 nm where the background absorption of hemoglobin is irrelevant considering the amount of serum used in the reaction. In addition, the background is corrected by performing the first measure after the addition of sample, buffer, and reagent. Hyperbilirubinemia also does not affect the cCRP concentration measured by our assay, in contrast to the cCRP results obtained by ELISA. 29 The maximum concentrations of the substances tested in our study are similar or higher than those evaluated in other cCRP method studies. 15, 29 When the analytical results, obtained with the Gentian assay and the new turbidimetric immunoassay were compared, only small proportional and constant errors were detected. The agreement between the new turbidimetric immunoassay and the Gentian method can be considered very good, taking into account that the assays use different unrelated standards for calibration. Furthermore, the analysis of differences showed limits of agreement that can be considered acceptable according to the total allowable error of 29.6% previously determined for cCRP measurements and based on T A B L E 5 . The interference study was performed by measuring canine CRP (cCRP) concentrations in serum samples supplemented with increasing amounts of hemoglobin, bilirubin, and triglycerides. Interference was defined as the bias between cCRP concentrations measured in the supplemented sample compared with that measured in the unsupplemented control samples and expressed as a percentage of the control. Fund (ERDF).
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